
    
      This will be a phase II, multi-centre, randomized, double-blind, placebo-controlled study
      designed to assess preliminary efficacy, safety and pharmacokinetics (PK) of 2-7 days
      continuous IV administration of sevuparin for the management of acute VOC in subjects with
      SCD.

      Adults and adolescents â‰¥ 12 years of age will be randomized to treatment with sevuparin or
      placebo (ratio 1:1).
    
  